Skip to main content

Sklamberg Quoted in The Pink Sheet on Proposed HHS Regulatory Review

November 6, 2020

Life Sciences & Healthcare Regulatory partner Howard Sklamberg was quoted in an article from The Pink Sheet, "HHS Regulatory Reform Proposal Seen As Blunt Instrument That Could Burden Industry and Agencies." The article examines industry feedback on a new HHS proposal designed to enforce retrospective regulation review at the FDA and CMS.

» Read the full article (subscription required).